Guggenheim Maintains a Buy Rating on Eli Lilly and Company (LLY), Sets a $875 PT

Eli Lilly and Company (NYSE:LLY) is one of the best stocks to invest in for the long term. In a report released on August 13, Seamus Fernandez from Guggenheim maintained a Buy rating on Eli Lilly and Company (NYSE:LLY) and set a price target of $875.00.

The rating update came after Eli Lilly and Company (NYSE:LLY) reported its fiscal Q2 2025 earnings on August 7, with revenue growing 38% to $15.56 billion, driven primarily by volume growth from Zepbound and Mounjaro.

Eli Lilly and Company (NYSE:LLY) raised the midpoint of its 2025 full-year revenue guidance by $1.5 billion, taking it to the $60 billion to $62 billion range. It also raised its reported EPS guidance to be in the $20.85 to $22.10 range.

Eli Lilly and Company (NYSE:LLY) develops, manufactures, discovers, and sells pharmaceutical products. These products span oncology, diabetes, immunology, neuroscience, and other therapies.

While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.